sponsored
PatientsVille.com Logo

PatientsVille

Measles Medical Research Studies

Up-to-date List of Measles Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Measles Medical Research Studies

Rank Status Study
1 Recruiting Additional Measles Vaccine at 4 Months of Age
Condition: Measles Infection
Intervention: Biological: Measles vaccine
Outcome Measures: Mortality;   Morbidity;   Hospitalisations/consultations;   Growth;   Measles infection
2 Unknown  Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Measles
Intervention: Biological: attenuated Measles vaccine
Outcome Measures: To assess progression-free survival (PFS) and overall survival (OS) in patients with NSCLC in remission receiving subcutaneous live-attenuated Measles virus vaccine as consolidation therapy in patients with Measles-positive tumors.;   To evaluate additional measures of efficacy, safety, and disease/treatment-related symptoms.
3 Unknown  Ontogeny of Measles Immunity in Infants
Condition: Measles
Interventions: Biological: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous);   Biological: MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
Outcome Measures: Immune response to Measles vaccine;   Affect of maternal antibodies on immune response to Measles vaccine.
4 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality
Condition: Measles Vaccine
Intervention: Biological: Early Measles vaccine
Outcome Measures: Mortality;   Morbidity;   Growth;   Antibody titres
5 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Condition: Measles Vaccine
Intervention: Biological: Early Measles vaccine
Outcome Measures: Mortality;   Morbidity;   Growth;   Antibody titres
6 Not yet recruiting Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Outcome Measures: Evaluation of immunogenicity of the study vaccines in terms of antibody concentration;   Evaluation of immunogenicity of the study vaccines in terms of seroresponse;   A minimum 4-fold rise in anti-Measles, anti-mumps and anti-rubella virus antibody concentration;   Occurrence of solicited local and general symptoms;   Occurrence of unsolicited adverse events (AEs);   Occurrence of pre-specified AEs;   Occurrence of Serious Adverse Events (SAEs)
7 Unknown  Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Condition: Measles
Intervention:
Outcome Measure:
8 Recruiting The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Conditions: Mortality;   Vaccines
Intervention: Biological: Providing Measles vaccine for all children 9-35 months who have not yet received a routine Measles vaccine
Outcome Measures: Mortality;   Hospital morbidity
9 Not yet recruiting Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
Outcome Measures: Immunogenicity comparing the 3 lots of MMR vaccine produced totally in Brazil and reference vaccine.;   Safety;   Determine the consistency of production;   Adverse events after tetraviral;   Seroconversion after vaccine tetraviral( Measles, mumps,rubella and varicela)
10 Recruiting Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Condition: Measles
Intervention: Biological: MMR vaccination
Outcome Measures: serologic response to MMR vaccine in seronegative transplant recipients;   Persistance of seroresponse to MMR vaccine
11 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
Outcome Measures: Immunogenicity with respect to the components of the Inv_MMR vaccine as compared to Com_MMR vaccine when given with VV and DTaP-IPV vaccines in terms of antibody concentration;   Immunogenicity with respect to the components of the Inv_MMR vaccine as compared to Com_MMR vaccine when given without VV and DTaP-IPV in terms of antibody concentration;   Immunogenicity with respect to VV in terms of antibody concentration;   Immunogenicity with respect to the components of DTaP- IPV vaccine in terms of antibody concentration;   Occurrence of solicited local symptoms;   Occurrence of solicited general symptoms;   Occurrence of Adverse events of specific interest;   Occurrence of Unsolicited adverse events;   Occurrence of serious adverse events
12 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals Measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II, combined Measles-mumps-rubella virus vaccine live.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
Outcome Measures: Immunogenicity of the MMR vaccines;   Immunogenicity of the MMR vaccines post-dose 2 (US post-dose 2 sub-cohort) in terms of antibody concentration.;   Occurrence of solicited local symptoms.;   Occurrence of solicited general symptoms.;   Occurrence of Unsolicited adverse events.;   Occurrence of Adverse events of specific interest.;   Serious adverse events (SAEs).
13 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic Measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
Outcome Measures: Adverse event (AE) profile;   Describe the safety of the intrapleural administration of MV-NIS in patients with malignant pleural mesothelioma for all cycles out to 90 days.
14 Recruiting Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
Outcome Measure: Whether the lower immunogenicity of the mumps component obtained in clinical studies with the MMR in Brazil, due to the multidose presentation.
15 Unknown  The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
Conditions: Immunity;   Measles;   Mumps;   Rubella
Interventions: Dietary Supplement: Probiotics (L.acidophilus and B.lactis);   Dietary Supplement: Cornflor
Outcome Measures: The level of antibodies against Measles, Mumps, Rubella and Varicella in the study group compared to the placebo group.;   The number of vaccine-related adverse events in the study group compared to the placebo group.
16 Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Conditions: Rubella;   Measles;   Mumps
Interventions: Biological: GSK Biologicals Measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined Measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
Outcome Measures: Immunogenicity of the MMR vaccines in terms of antibody concentration;   Immunogenicity of the Varivax, Havrix and Prevnar 13 vaccines in a subset of children, in terms of antibody concentrations;   Complementary read-out for immunogenicity of the MMR vaccines in terms of antibody concentration;   Occurrence of solicited local symptoms;   Occurrence of solicited general symptoms;   Occurrence of Unsolicited adverse events;   Occurrence of Adverse events of specific interest;   Occurrence of Serious adverse events (SAEs)
17 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing Measles virus;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy
Outcome Measures: Adverse events profile, in terms of number and severity of all adverse events, as assessed by NCI CTCAE v3.0;   Overall toxicity incidence and toxicity profile (by dose level, patient, and tumor site) as assessed by NCI CTCAE v3.0;   Time until any treatment related toxicity;   Time until treatment-related toxicity ≥ grade 3;   Time until hematologic nadirs (WBC, absolute neutrophil count, platelet count);   Maximum tolerated dose of vaccine as assessed by NCI CTCAE v3.0;   Correlate viremia, human CEA titers, viral propagation in tumor, viral shedding, CD46 status, delayed-type hypersensitivity results, CD4 and CD8 counts, lymphoproliferative assay, and ELISPOT assay with response and toxicity;   Viral gene expression at each dose level as assessed by CEA titer;   Viremia following intratumoral administration of vaccine as assessed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) of peripheral blood mononuclear cells;   Measles virus shedding/persistence following intratumoral administration of vaccine as assessed by RT-PCR;   Viral replication following intratumoral administration of vaccine as assessed by in situ hybridization and Vero cell overlay;   CR, PR, regress, stable dis, & prog dis by neur exam, MRI, and/or CT scan for bidimens. meas. dis & eval dis. at baseline, 28 days after resection, and then every 2 mo. until progr.;   Humoral and cell. imm. resp. by antiMeasles virus-specific antibody level (IgG) at baseline, 28 days after resection, and every 2 mo until prog;   Humoral and cell. imm. resp. by lymphoproliferative assay and interferon-gamma ELISPOT assay performed at baseline and at 28 days after tumor resection;   Progression-free survival at 3 and 6 months;   Time to disease progression;   Time to treatment failure (due to progression, unacceptable toxicity, or refusal to continue participation by the patient)
18 Recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Procedure: mesenchymal stem cell transplantation;   Biological: oncolytic Measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I);   Number and severity of adverse events (Phase I);   Overall toxicity incidence (Phase I);   Toxicity profiles by dose level and patient (Phase I);   Proportion of patients alive and progression-free at 4 months (Phase II);   Tumor response defined as complete response or partial response (Phase II);   Overall survival (Phase II);   Progression free survival (Phase II);   Maximum grade for each type of toxicity (Phase II)
19 Not yet recruiting Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants
Conditions: Cholera;   Diarrhea;   Vibrio Infections
Interventions: Biological: Bivalent killed oral cholera vaccine;   Biological: Killed Escherichia coli K12 placebo
Outcome Measures: Safety: proportion of subjects with diarrhea;   Immunogenicity: proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies, relative to baseline;   Geometric mean serum vibriocidal titers;   Proportion of subjects with any of the following: a) immediate reactions 30 minutes and up to 3 days after each dose, b) serious adverse events occurring during the trial, c) any adverse event;   Proportion of subjects with ≥ 0.1 mIU/ml of anti-diphtheria toxoid antibodies;   Proportion of subjects with ≥ 0.1 mIU/ml of anti-tetanus toxoid antibodies;   For initially seronegative subjects: proportion of subjects with ≥ 15 EU/ml of anti-pertussis IgG and for initially seropositive subjects, proportion with antibody titers equal to or greater than the initial titers prior to vaccination;   Proportion of subjects with ≥ 10 mIU/ml of anti-HbS antibody;   Proportion of subjects with ≥ 8 fold dilution of anti-polio virus 1, 2, or 3 antibodies by micro-neutralization test;   Proportion of subjects with >150 mIU/ml Measles IgG antibodies
20 Recruiting Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Conditions: Immunogenicity;   Reactogenicity
Intervention: Biological: Trivivac vaccine
Outcome Measures: Immunogenicity as measured by the proportion of subjects achieving seroprotection against Measles, mumps and rubella;   Reactogenicity as measured by the prevalence of local and systemic adverese reaction

These studies may lead to new treatments and are adding insight into Measles etiology and treatment.

A major focus of Measles research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Measles